融合中西医元素的哮喘前期人群特征与疾病演变规律的前瞻性队列研究

注册号:

Registration number:

ITMCTR2025000362

最近更新日期:

Date of Last Refreshed on:

2025-02-19

注册时间:

Date of Registration:

2025-02-19

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

融合中西医元素的哮喘前期人群特征与疾病演变规律的前瞻性队列研究

Public title:

A prospective cohort study of the characteristics of the pre-asthma population and the evolution of the disease integrating elements of traditional Chinese and Western medicine

注册题目简写:

哮喘前期的人群特征与疾病演变

English Acronym:

Pre-Asthma Characteristics and Evolution Study(PACE Study)

研究课题的正式科学名称:

融合中西医元素的哮喘前期人群特征与疾病演变规律的前瞻性队列研究

Scientific title:

A prospective cohort study of the characteristics of the pre-asthma population and the evolution of the disease integrating elements of traditional Chinese and Western medicine

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

刘霁辉

研究负责人:

陈远彬

Applicant:

Jihui Liu

Study leader:

Yuanbin Chen

申请注册联系人电话:

Applicant telephone:

15241479057

研究负责人电话:

Study leader's telephone:

15920174645

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1795137957@qq.com

研究负责人电子邮件:

Study leader's E-mail:

chenyuanbin110@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

广东省广州市越秀区大德路111号

研究负责人通讯地址:

广东省广州市越秀区大德路111号

Applicant address:

111 Dade Road Yuexiu District Guangzhou Guangdong

Study leader's address:

111 Dade Road Yuexiu District Guangzhou Guangdong

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

广东省中医院

Applicant's institution:

Guangdong Provincial Hospital of Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

BE2024-348-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

广东省中医院伦理委员会

Name of the ethic committee:

Ethics Committee of Guangdong Provincial Hospital of Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2024/12/9 0:00:00

伦理委员会联系人:

李晓彦

Contact Name of the ethic committee:

Xiaoyan Li

伦理委员会联系地址:

广东省广州市越秀区大德路111号

Contact Address of the ethic committee:

111 Dade Road Yuexiu District Guangzhou Guangdong

伦理委员会联系人电话:

Contact phone of the ethic committee:

02081887233

伦理委员会联系人邮箱:

Contact email of the ethic committee:

llbgs@gzucm.edu.cn

研究实施负责(组长)单位:

广东省中医院

Primary sponsor:

Guangdong Provincial Hospital of Chinese Medicine

研究实施负责(组长)单位地址:

广东省广州市越秀区大德路111号

Primary sponsor's address:

111 Dade Road Yuexiu District Guangzhou Guangdong

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

广州

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

广州市番禺区中医院

具体地址:

广州市番禺区市桥街桥东路65号、93号

Institution
hospital:

Panyu District Hospital of Traditional Chinese Medicine Guangzhou

Address:

No. 65 and No. 93 Qiaodong Road Shiqiao Street Panyu District Guangzhou

国家:

中国

省(直辖市):

广东

市(区县):

广州

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

广东省中医院

具体地址:

广东省广州市越秀区大德路111号

Institution
hospital:

Guangdong Provincial Hospital of Chinese Medicine

Address:

111 Dade Road Yuexiu District Guangzhou Guangdong

国家:

中国

省(直辖市):

湖南

市(区县):

株洲

Country:

China

Province:

Hunan

City:

Zhuzhou

单位(医院):

湖南省直中医医院

具体地址:

湖南株洲市人民路571号

Institution
hospital:

Hunan Provincial Hospital of Traditional Chinese Medicine

Address:

No. 571 Renmin Road Zhuzhou City Hunan

国家:

中国

省(直辖市):

山东

市(区县):

烟台

Country:

China

Province:

Shandong

City:

Yantai

单位(医院):

烟台市中医医院

具体地址:

烟台市幸福路39号

Institution
hospital:

Yantai Hospital of Traditional Chinese Medicine

Address:

No. 39 Xingfu Road Yantai City

国家:

中国

省(直辖市):

广东

市(区县):

中山

Country:

China

Province:

Guangdong

City:

Zhongshan

单位(医院):

中山市中医院

具体地址:

广东省中山市西区康欣路3号

Institution
hospital:

Zhongshan Hospital of Traditional Chinese Medicine

Address:

No. 3 Kangxin Road West District Zhongshan City Guangdong Province

经费或物资来源:

广州市中医药防治慢性咳喘病重点实验室

Source(s) of funding:

Guangzhou Key Laboratory of Traditional Chinese Medicine for the Prevention and Treatment of Chronic Cough and Dyspnea

研究疾病:

哮喘前期

研究疾病代码:

Target disease:

Pre-asthma

Target disease code:

研究类型:

Study type:

观察性研究

Observational study

研究设计:

Study design:

队列研究

Cohort study

研究所处阶段:

Study phase:

其它

Others

研究目的:

建立哮喘前期人群队列,明确人群的中西医临床特征,构建哮喘发病的风险预测模型,实现前期高危风险患者的早期预警,为中西医结合早期防控哮喘提供参考依据。

Objectives of Study:

Establish a pre-asthma population cohort to elucidate the clinical characteristics of this population from both traditional Chinese and Western medical perspectives. Develop a risk prediction model for asthma onset enabling early identification and warning of high-risk patients in the initial stages. This approach aims to provide a valuable reference for the early prevention and management of asthma through the integration of traditional Chinese and Western medicine.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

哮喘前期: (1)年龄≥18岁,男女均可; (2)符合哮喘前期的诊断标准; (3)患者知情并签署知情同意书。 轻度哮喘: (1)年龄≥18岁,男女均可; (2)符合轻度的诊断标准; (3)患者知情并签署知情同意书。 健康志愿者: (1)年龄≥18岁,男女均可; (2)近一年体检未发现明显异常; (3)患者知情并签署知情同意书。

Inclusion criteria

Pre-asthma (1) Age≥ 18 years old male or female; (2) meet the diagnostic criteria for pre-asthma; (3) The patient is informed and signs the informed consent form. Mild asthma: (1) Age≥ 18 years old male or female; (2) meet the diagnostic criteria for mild; (3) The patient is informed and signs the informed consent form. Healthy Volunteers: (1) Age≥ 18 years old male or female; (2) No obvious abnormalities were found in the physical examination in the past year; (3) The patient is informed and signs the informed consent form.

排除标准:

哮喘前期: (1)既往已确诊哮喘; (2)合并慢阻肺、支气管扩张、间质性肺病、阻塞性睡眠呼吸暂停综合征、肺恶性肿瘤、活动性肺结核等疾病; (3)近1个月内曾发现急性上呼吸道感染或肺炎; (4)合并严重心脑血管(包括恶性心律失常、急性心肌梗死、心功能4级、急性脑卒中等)、血液系统疾病; (5)合并严重肝肾疾病,包括失代偿性肝硬化、门静脉高压或门静脉曲张引起出血、肾透析等; (6)合并免疫缺陷,如恶性肿瘤、器官/骨髓移植、HIV感染; (7)有精神疾患或认知障碍者。 轻度哮喘: (1)合并慢阻肺、支气管扩张、间质性肺病、阻塞性睡眠呼吸暂停综合征、肺恶性肿瘤、活动性肺结核等疾病; (2)合并严重心脑血管(包括恶性心律失常、急性心肌梗死、心功能4级、急性脑卒中等)、血液系统疾病; (3)合并严重肝肾疾病,包括失代偿性肝硬化、门静脉高压或门静脉曲张引起出血、肾透析等; (4)合并免疫缺陷,如恶性肿瘤、器官/骨髓移植、HIV感染; (5)有精神疾患或认知障碍者。 健康志愿者: (1)既往已确诊哮喘; (2)合并慢阻肺、支气管扩张、间质性肺病、阻塞性睡眠呼吸暂停综合征、肺恶性肿瘤、活动性肺结核等疾病; (3)合并有过敏性鼻炎、湿疹、荨麻疹、特应性皮炎、过敏性结膜炎等过敏性疾病者; (4)既往有药物或食物过敏史; (5)近1个月内曾发现急性上呼吸道感染或肺炎; (6)有吸烟史或肺部相关的手术史者; (7)合并其他脏器(如心、脑、肝、肾等)较严重的原发性疾病或恶性肿瘤的患者; (8)合并有系统性红斑狼疮、干燥综合征、类风湿性关节炎等免疫相关性疾病者; (9)有精神疾患或认知障碍者;

Exclusion criteria:

Pre-asthma (1) Previous diagnosis of asthma; (2) Combined with chronic obstructive pulmonary disease bronchiectasis interstitial lung disease obstructive sleep apnea syndrome pulmonary malignancy active tuberculosis and other diseases; (3) Acute upper respiratory tract infection or pneumonia has been found in the past 1 month; (4) Severe cardiovascular and cerebrovascular diseases (including malignant arrhythmia acute myocardial infarction cardiac function grade 4 acute stroke etc.) and hematological diseases; (5) Combined with severe liver and kidney diseases including decompensated liver cirrhosis hemorrhage caused by portal hypertension or portal varices renal dialysis etc.; (6) Combined immunodeficiency such as malignant tumors organ/bone marrow transplantation HIV infection; (7) Those with mental disorders or cognitive disabilities. Mild asthma: (1) Combined with chronic obstructive pulmonary disease bronchiectasis interstitial lung disease obstructive sleep apnea syndrome pulmonary malignancy active tuberculosis and other diseases; (2) Severe cardiovascular and cerebrovascular diseases (including malignant arrhythmia acute myocardial infarction grade 4 cardiac function acute stroke etc.) and hematological diseases; (3) Combined with severe liver and kidney diseases including decompensated liver cirrhosis hemorrhage caused by portal hypertension or portal varices renal dialysis etc.; (4) Immunodeficiency such as malignant tumors organ/bone marrow transplantation HIV infection; (5) Those with mental disorders or cognitive disabilities. Healthy Volunteers: (1) Previous diagnosis of asthma; (2) Combined with chronic obstructive pulmonary disease bronchiectasis interstitial lung disease obstructive sleep apnea syndrome pulmonary malignancy active tuberculosis and other diseases; (3) Patients with allergic rhinitis eczema urticaria atopic dermatitis allergic conjunctivitis and other allergic diseases; (4) History of drug or food allergies in the past; (5) Acute upper respiratory tract infection or pneumonia has been found in the past 1 month; (6) Those with a history of smoking or lung-related surgeries; (7) Patients with serious primary diseases or malignant tumors of other organs (such as heart brain liver kidney etc.); (8) Patients with immune-related diseases such as systemic lupus erythematosus Sjögren's syndrome rheumatoid arthritis etc.; (9) Those with mental disorders or cognitive disabilities;

研究实施时间:

Study execute time:

From 2024-12-31

To      2029-12-31

征募观察对象时间:

Recruiting time:

From 2025-03-01

To      2029-12-31

干预措施:

Interventions:

组别:

轻度哮喘

样本量:

200

Group:

Mild asthma

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

哮喘前期

样本量:

1000

Group:

Pre-asthma

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

健康人群

样本量:

100

Group:

Healthy people

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

样本总量 Total sample size : 1300

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

广东

市(区县):

广州

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

广东省中医院

单位级别:

三级甲等

Institution/hospital:

Guangdong Provincial Hospital of Chinese Medicine

Level of the institution:

Grade A tertiary hospital

国家:

中国

省(直辖市):

广东

市(区县):

中山

Country:

China

Province:

Guangdong

City:

Zhongshan

单位(医院):

中山市中医院

单位级别:

三级甲等

Institution/hospital:

Zhongshan Hospital of Traditional Chinese Medicine

Level of the institution:

Grade A tertiary hospital

国家:

中国

省(直辖市):

广东

市(区县):

广州

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

广州市番禺区中医院

单位级别:

三级甲等

Institution/hospital:

Panyu District Hospital of Traditional Chinese Medicine Guangzhou

Level of the institution:

Grade A tertiary hospital

国家:

中国

省(直辖市):

湖南

市(区县):

株洲

Country:

China

Province:

Hunan

City:

Zhuzhou

单位(医院):

湖南省直中医医院

单位级别:

三级甲等

Institution/hospital:

Hunan Provincial Hospital of Traditional Chinese Medicine

Level of the institution:

Grade A tertiary hospital

国家:

中国

省(直辖市):

山东

市(区县):

烟台

Country:

China

Province:

Shandong

City:

Yantai

单位(医院):

烟台市中医医院

单位级别:

三级甲等

Institution/hospital:

Yantai Hospital of Traditional Chinese Medicine

Level of the institution:

Grade A tertiary hospital

测量指标:

Outcomes:

指标中文名:

支气管舒张试验阴性率

指标类型:

次要指标

Outcome:

Negative rate of bronchial dilation test

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

FeNO数值变化

指标类型:

次要指标

Outcome:

Change in FeNO value

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中医湿证积分分布及变化

指标类型:

次要指标

Outcome:

Distribution and change of TCM wet syndrome points

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

支气管激发试验阴性率

指标类型:

次要指标

Outcome:

Negative rate of bronchial provocation test

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

FEV1、FVC、FEV1/FVC、MMEF、FEF50、FEF75的谷值和峰值变化

指标类型:

次要指标

Outcome:

Valleys and peak changes of FEV1 FVC FEV1/FVC MMEF FEF50 FEF75

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中医证候分布及变化

指标类型:

次要指标

Outcome:

Distribution and changes of TCM syndromes

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

支气管舒张试验阳性率

指标类型:

次要指标

Outcome:

Positive rate of bronchial dilation test

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

哮喘发病率

指标类型:

主要指标

Outcome:

Asthma incidence

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肺功能FEV1、FVC峰值和谷值的年下降速率

指标类型:

次要指标

Outcome:

Annual rate of decline in peak and trough values of FEV1 and FVC in lung function

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

急性发作发生率

指标类型:

次要指标

Outcome:

Incidence of exacerbations

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

支气管激发试验阳性率

指标类型:

次要指标

Outcome:

Positive rate of bronchial provocation test

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中医体质评估分布及变化

指标类型:

次要指标

Outcome:

The distribution and change of TCM constitution assessment

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

哮喘前期患者的人群特征

指标类型:

次要指标

Outcome:

Demographic characteristics of patients with pre-asthma

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

咳嗽程度评分表(CET)的变化

指标类型:

次要指标

Outcome:

Change in Cough Degree Score (CET).

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

哮喘控制评分,包括ACT和ACQ的变化

指标类型:

次要指标

Outcome:

Asthma control scores including changes in ACT and ACQ

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

痰液

组织:

Sample Name:

Sputum

Tissue:

人体标本去向

使用后保存

说明

保存年限不超过10年

Fate of sample 

Preservation after use

Note:

The shelf life does not exceed 10 years

标本中文名:

血浆

组织:

Sample Name:

plasma

Tissue:

人体标本去向

使用后保存

说明

保存年限不超过10年

Fate of sample 

Preservation after use

Note:

The shelf life does not exceed 10 years

标本中文名:

血清

组织:

Sample Name:

serum

Tissue:

人体标本去向

使用后保存

说明

保存年限不超过10年

Fate of sample 

Preservation after use

Note:

The shelf life does not exceed 10 years

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 18
Min age years
最大 99
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

无需随机

Randomization Procedure (please state who generates the random number sequence and by what method):

Not need to random

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

非共享,数据将以论文形式发表

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The data is not shared and will be published in the form of papers

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病历记录表CRF

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统